PMID- 31452747
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 18
IP  - 3
DP  - 2019 Sep
TI  - Sulforaphane-induced epigenetic regulation of Nrf2 expression by DNA 
      methyltransferase in human Caco-2 cells.
PG  - 2639-2647
LID - 10.3892/ol.2019.10569 [doi]
AB  - The present study aimed to investigate the mechanism underlying 
      sulforaphane-mediated epigenetic regulation of nuclear factor-erythroid derived 
      2-like 2 (Nrf2) expression in human colon cancer. Proteins were extracted from 
      normal Caco-2 cells using sulforaphane and 5-aza-2'-deoxycytidine (5-Aza) 
      combined with trichostatin A (TSA). The mRNA and protein expression levels and 
      activity of DNA methyltransferase 1 (DNMT1) were determined. Methylation-specific 
      polymerase chain reaction and bisulfite genomic sequencing were also used to 
      measure the methylation levels of CpG sites in the Nrf2 promoter region. Nrf2 
      expression was measured using reverse transcription-quantitative PCR and western 
      blot analysis. The results demonstrated that sulforaphane did not affect DNMT1 
      mRNA expression levels. DNMT1 protein expression was inhibited by sulforaphane 
      and 5-Aza co-treatment with TSA. Nrf2 promoter methylation decreased 
      significantly in the sulforaphane group compared with the control group. Nrf2 
      promoter methylation level in the 5-Aza+TSA group was the lowest among all 
      groups. Nrf2 mRNA levels exhibited significant differences between the 
      sulforaphane-treated and control groups, as well as between the 5-Aza+TSA and 
      control groups, and the sulforaphane-treated and 5-Aza+TSA groups. Nrf2 protein 
      expression was also inhibited by sulforaphane, as well as 5-Aza co-treatment with 
      TSA. The results revealed that sulforaphane may promote demethylation of the Nrf2 
      promoter region to increase activation of Nrf2, which induces chemoprevention of 
      colon cancer.
FAU - Zhou, Jia-Wei
AU  - Zhou JW
AD  - Medical School, Qi-Lu Hospital of Shandong University, Jinan, Shandong 250012, 
      P.R. China.
FAU - Wang, Min
AU  - Wang M
AD  - Department of of Geriatric Gastroenterology, Qi-Lu Hospital of Shandong 
      University, Jinan, Shandong 250012, P.R. China.
AD  - Department of General Practice, Qi-Lu Hospital of Shandong University, Jinan, 
      Shandong 250012, P.R. China.
FAU - Sun, Nuan-Xin
AU  - Sun NX
AD  - Jiangxi Medical College of Nanchang University, Nanchang, Jiangxi 330006, P.R. 
      China.
FAU - Qing, Ying
AU  - Qing Y
AD  - Department of General Practice, Qi-Lu Hospital of Shandong University, Jinan, 
      Shandong 250012, P.R. China.
FAU - Yin, Teng-Fei
AU  - Yin TF
AD  - Department of General Practice, Qi-Lu Hospital of Shandong University, Jinan, 
      Shandong 250012, P.R. China.
FAU - Li, Cui
AU  - Li C
AD  - Department of General Practice, Qi-Lu Hospital of Shandong University, Jinan, 
      Shandong 250012, P.R. China.
FAU - Wu, Dong
AU  - Wu D
AD  - Department of General Surgery, Qi-Lu Hospital of Shandong University, Jinan, 
      Shandong 250012, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190705
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6676568
OTO - NOTNLM
OT  - chemoprevention
OT  - colon tumour
OT  - epigenetic regulation
OT  - nuclear factor-erythroid derived 2-like 2
OT  - sulforaphane
EDAT- 2019/08/28 06:00
MHDA- 2019/08/28 06:01
PMCR- 2019/07/05
CRDT- 2019/08/28 06:00
PHST- 2018/05/24 00:00 [received]
PHST- 2019/05/24 00:00 [accepted]
PHST- 2019/08/28 06:00 [entrez]
PHST- 2019/08/28 06:00 [pubmed]
PHST- 2019/08/28 06:01 [medline]
PHST- 2019/07/05 00:00 [pmc-release]
AID - OL-0-0-10569 [pii]
AID - 10.3892/ol.2019.10569 [doi]
PST - ppublish
SO  - Oncol Lett. 2019 Sep;18(3):2639-2647. doi: 10.3892/ol.2019.10569. Epub 2019 Jul 
      5.